An association between diet, metabolic syndrome and lower urinary tract symptoms  by Adedeji, T.G. et al.
African Journal of Urology (2016) 22, 61–66
African  Journal  of  Urology
Official journal of the Pan African Urological Surgeon’s Association
web page of the journal
www.ees.elsevier.com/afju
www.sciencedirect.com
BPH and Prostate Diseases
Review
An  association  between  diet,  metabolic
syndrome  and  lower  urinary  tract  symptoms
T.G.  Adedeji a,c,  A.A.  Fasanmade a,  E.O.  Olapade-Olaopa b,c,∗
a Department  of  Physiology,  University  of  Ibadan
b Department  of  Surgery,  University  of  Ibadan  and  University  College  Hospital,  Ibadan
c PIUTA  Ibadan  Centre,  Department  of  Surgery,  University  of  Ibadan  and  University  College  Hospital,  Ibadan,
Nigeria
Received 22 December 2014; received in revised form 20 November 2015; accepted 28 November 2015
Available online 4 May 2016
KEYWORDS
Diet;
Metabolic syndrome;
CRP;
Lower urinary tract
symptoms;
Testosterone
Abstract
Diet is a key factor in the aetiology of many diseases, including metabolic syndrome and lower urinary
tract disorders. Metabolic syndrome is a growing and increasingly expensive health problem in both the
developed and the developing world, with an associated rise in morbidity and mortality. On the other
hand, lower urinary tract symptoms affect millions of individuals worldwide, lowering their quality of
life. Associations have been established between both conditions in existing literature and the various
components of the metabolic syndrome have been linked with the onset and aggravation of symptoms in
various forms of LUTS. This current review explores the relationships between these in detail, focusing on
their inter-relationships particularly vis-a-vis dietary macronutrient and micronutrient intake.
© 2016 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. All rights reserved.
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1110-5704/© 2016 Pan African Urological Surgeons’ Association. Production anNCDs). Diet, being one of the very key environmental factors,
s capable of affecting health at the gross level, and at the genetic
evel through gene–nutrient interactions. Increasingly, diet is being
ecognised as playing a crucial role in the mechanisms involved in
he pathophysiology and genetic predisposition, as well as the devel-
pment and/or progression of diseases. This is due in large part to
n increase in the consumption of ‘western diets’, which is being
ncreasingly adopted by the developing societies.iet is the type of food, containing different nutrients in vary-
ng compositions, regularly consumed by an individual. The main
acronutrients in diet are proteins, carbohydrates and fats, and these
d hosting by Elsevier B.V. All rights reserved.
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re varied in each diet according to choice, culture, health status, and
conomic strength of an individual. At the cellular level, these vary-
ng nutrients are absorbed and utilised for energy in the body through
he body’s metabolic processes [1]. Nutritionally poor diets have
een linked to several chronic NCDs including metabolic syndrome
MetS) [2], a disorder which primarily originates from morbid obe-
ity, often as a consequence of a high-fat diet. A ‘balanced’ diet
s a diet which contains all of the individual macronutrients (and
icronutrients) required for the optimal wellbeing and health of an
ndividual. However, diets high in fats and carbohydrates are com-
only consumed and these have been linked to several metabolic
isorders.
etS is an aggregation of disorders which include elevated trigly-
erides and apoprotein B – containing lipoproteins, reduced High
ensity Lipoprotein (HDL), arterial blood pressure elevation, and
mbalances in glucose homeostasis with the main manifestations of
his syndrome however being insulin resistance and abdominal obe-
ity [3]. This syndrome is a global problem which has long posed a
hallenge to the developed world, and increasingly so to the devel-
ping societies of the world. Its incidence and prevalence is high
n many countries amounting to a high socioeconomic cost, espe-
ially in costs of management of affected. MetS has been described
s a major factor in the aetiology of lower urinary tract symptoms
LUTS) [3], increasing both predisposition to the disorder and the
ggressiveness of the symptoms. Also, individual components of
etS have been reported to have strong associations with LUTS [4].
ower urinary tract symptoms have been established as having a
eleterious influence on quality of life for of adults irrespective
f age, sex, and subpopulation [5]. The International Continence
ociety (ICS) has characterised LUTS into three classes which are
torage, voiding, and post-micturition symptoms [6]. LUTS are
ften described in relation to benign prostatic hyperplasia (BPH)
n men, especially those older than 60 years. However, LUTS could
riginate from other sources (see Fig. 1 below) [7] and the diet of
n individual, especially elderly males, could be a predisposing fac-
or. The commonest causes of LUTS include, (1) Diabetes mellitus
ig.  1  European Association of Urology guidelines for factors caus-
ng LUTS [10].
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2) Overactive bladder which has been described as “a syndrome
ith urgency, with or without associated urine incontinence and
sually accompanied by higher urinary frequency and nocturia”
8], and (3) Bladder Outlet Obstruction especially that secondary
o benign prostatic hyperplasia which has a high prevalence, espe-
ially in older males. Despite the high prevalence of the latter two
iseases, the mechanisms responsible for the voiding dysfunction
re still a focus of intense research efforts.
ssociations  between  metabolic  syndrome  and  lower  urinary
ract  symptoms
ype II diabetes mellitus has a strong association with moderate to
evere LUTS. Besides being implicated in the origin of LUTS, DM
as also been established as a deleterious factor in the more com-
on LUTS, having an adverse effect on the bladder. More than
alf of patients have been established as demonstrating bladder
bnormalities characterised by increased bladder capacity, weak-
ned sensation, poor contractility, and increased postvoid residual
rine [9]. Diabetic bladder dysfunction could be induced by diabetic
europathy and/or the osmotic diuresis associated with diabetes
ellitus [10,11]. Lee et al. reported that a high LUTS score might
e a good marker for assessing diabetic bladder dysfunction [12].
educed testosterone concentrations are also associated with the
etabolic syndrome. In the InCHIANTI study, the testosterone level
as significantly reduced in elderly male participants with MetS
13]. A negative correlation was also reported for waist circumfer-
nce and total testosterone in a study carried out in Argentina [14].
ecreased testosterone in MetS is attributable to the insulin resis-
ance which results in hyperinsulinaemia. The increased insulin in
irculation inhibits testosterone production by the Leydig cells [15].
ncrease in adipocytokines is also another key factor responsible for
ow testosterone production. Leptin is a hormone secreted by fat
ells which links food intake and energy expenditure to fat mass in
he body and an increase in its secretion has been linked with low
estosterone concentrations [16]. Also, of interest is the increase
n aromatase activity linked with MetS. Adipocytes secrete aro-
atase which catalyses conversion of testosterone to estradiol, and
ts increased secretion in MetS, secondary to increased fat mass,
esults in a decrease in testosterone level. Low testosterone has
een reported to have an inverse relationship to LUTS in men [17].
his interrelationship between MetS and LUTS could be adduced to
icroanatomical modifications which might result in loss of tissue
lasticity and fibrosis which, eventually may correspond with the
ffect of testosterone on penile tissue in men with hypogonadism
18]
nsulin has been described as an independent risk factor for stimula-
ion of prostatic hypertrophy in benign prostatic hyperplasia (BPH)
19]. Insulin resistance is one of the fundamental pathologies of
etS, which results in excessive insulin concentrations in blood
hyperinsulinaemia). Hyperinsulinaemia has been implicated as a
actor in increased tone of prostatic smooth muscle [20]. This will
ventually result in an increase in prostatic size and volume [21,22].
etS progression results in chronic inflammation and this has been
irectly associated with prostate enlargement [23]. The inflamma-
ion process is characterised by increased T-lymphocytic activity,
hich in the prostate may give rise to proliferation of both stromal
nd epithelial cells, and this repetitive and continuous damage to
he tissues followed by healing may eventually result in prostate
 trac
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enlargement. Prostatic enlargement precipitates BPH which is a
major cause of BOO, a key trigger of LUTS [3]. In the pathogene-
sis of MetS, insulin resistance has also been revealed as a cause of
increased sympathetic activity [24]. Hyperinsulinaemia induces an
increase in overall activity of the autonomic nervous system (ANS)
which will result in prostatic hypertrophy as well as overactivity of
the detrusor muscle. Stimulation of the 1-adrenoceptor has been
implicated in dynamic obstruction, a mediation which is because
of the associated increase in blood pressure [25]. Atherosclerosis
in MetS results in narrowing of blood vessels predisposing them to
chronic ischaemia. Pelvic ischaemia has been reported to decrease
bladder compliance and contractile force while increasing void fre-
quency in an animal model [26]. Narrowing of the blood vessels in
atherosclerosis causes a drastic reduction in blood flow to the bladder
during its filling. This processes of repeated ischaemia and subse-
quent reperfusion eventually stimulates high production of reactive
oxygen species (ROS) which damages bladder tissues.
Serum C-Reactive Protein (CRP) level is considered a surrogate
marker for chronic inflammation, a consideration which is synony-
mous to both metabolic syndrome and lower urinary tract symptoms,
and elevated serum CRP levels have been linked with both condi-
tions. CRP is produced by the liver in response to factors released by
adipocytes and tissue macrophages, enhancing phagocytosis [27].
In patients enrolled in the Reduction by Dutasteride of Prostate Can-
cer Event study (REDUCE study), histology of the prostate showed
chronic inflammation in 77.6% of men in prostatic biopsy speci-
mens at baseline, revealing conclusive evidence of a relationship
between the severity of LUTS and the degree of chronic inflamma-
tion [28]. A recent study has demonstrated a link between amount
of CRP in serum and BPH and LUTS and that it rose with increase
in age, PSA levels, as well as increased severity of LUTS, lower
void volumes, and increases in storage symptoms [29]. Multivariate
analysis also indicated that independent predictors associated with
an elevated serum CRP level were IPSS and age, suggesting that
increased serum CRP level can be associated with increased LUTS
in men with BPH [30]. Studies into bladder pain syndrome or inter-
stitial cystitis have also been providing increasing evidence which
suggests that it is associated with urothelial dysfunction and affer-
ent hyperexcitability due to neurogenic bladder inflammation [31].
Interestingly, high-sensitivity C-reactive protein (hs-CRP) level has
been very beneficial in predicting the risk of cardiovascular disease
and DM in asymptomatic people [32]. It is acknowledged as a very
sensitive predictor of Type 2 diabetes mellitus and coronary heart
disease and has been suggested for use as criteria for future defi-
nitions of metabolic syndrome [33]. Increase in serum CRP levels
have an established association with MetS risk factors and has been
shown to indicate a greater risk of cardiovascular disease [34].
Obesity, the precursor and predisposing factor to and a major com-
ponent of MetS, has been described as being a strong risk factor
for incontinence and LUTS and weight loss has been reported to
reduce the frequency of urinary incontinence [35]. The reported out-
comes of the Program to Reduce Incontinence by Diet and Exercise
(PRIDE) clinical trial, showed that women who were overweight
and obese presenting with urinary incontinence, when randomised
to lifestyle intervention showed great improvement in urinary incon-
tinence, especially for stress incontinence [36]. They described
clinically and statistically significant reductions in urinary incon-
tinent episodes with modest weight losses of 5–10%. In a different
study based on analysis of data from the third National Health and
Nutrition Examination Survey (NHANES III) and Healthy Eating
i
f
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at symptoms 63
ndex (HEI), an association was reported between unhealthy diet
onsumption and LUTS after the investigators had controlled for
ther known modifiable risk factors [37]. This cross-sectional study
arried out in the United States reported that a healthy diet (as
efined by USDA HEI) was associated with lower self-reported
UTS in men over the age of 40 years. It however found no evi-
ence to support a protective effect by any food group. They also
eported evidence of higher self-reported LUTS in blacks and His-
anics. Other studies in this line include the Olmsted County study
38], the Flint study [39], the UrEpik study [40], the third National
ealth and Nutrition Examination Survey (NHANES) [41], the
UNT study [42], and the Boston Area Community Health (BACH)
urvey [43]. Many of these studies reported significant associations
etween LUTS and factors like BMI (Body-Mass Index), Waist–Hip
atio, physical activity, diabetes mellitus as well as cardiovascular
iseases (especially those affecting the heart). The BACH survey
lso reported a relationship between cardiovascular diseases and
ncreased odds of LUTS and also that the effects of BMI and physical
ctivity on the odds of LUTS were most prominent in women [43].
iet,  metabolic  syndrome  and  lower  urinary  tract  symptoms
LUTS)
ll of the described origins of LUTS are influenced by macronutri-
nt intake and these have been established in many studies [44,45].
espite this, the extent of these relationships remains unclear and
ontroversial. Results from some studies in surgically treated BPH
ssessing effects of macronutrients on LUTS were inconsistent [46],
hilst another study established a positive relationship between total
at content of the body and BPH, while also reporting an inverse
ssociation between protein intake and BPH as defined by BPH
reatment or a high protein score [47].
t was earlier reported that men who consumed diets high in energy
ontent, especially those with high protein and polyunsaturated fatty
cid (PUFA) content, had a higher predisposition to BPH [48].
he Prostate Cancer Prevention Trial (PCPT) results confirmed
hat high fat diets and high red meat consumption were associated
ith increase in the risk of Benign Prostatic Hyperplasia (BPH),
hile observing that high vegetable intake resulted in a reduction of
he risk [49]. Several reports suggest that low fat/low energy diets,
specially those containing large amounts of fruits and vegetables
rich in β-carotene lutein or vitamin C), which are well-known to
rotect against obesity and the resultant MetS, could also be pro-
ective against LUTS [49,50]. Lower incidences of BPH/LUTS and
ther prostate-related conditions have been observed in some Asian
ountries when compared with Western nations. This has been sug-
ested to be related to the consumption of a mainly plant-based diet
n those Asian countries whereas the Western diet is predominantly
nimal-based [51]. It is believed that high intake of unsaturated fatty
cids might stimulate and worsen inflammation as well as impair
-reductase activity through a detrimental effect on the lipid mem-
rane via its peroxidation [52]. Maserejian et al. described a high
agnitude, dose-dependent association between high total energy
ntake and overall LUTS in women with low waist circumferences,
nd also reported that increased saturated fat intake was predictive
f post-micturition symptoms [53]. Metabolic factors, as well as its
ssociated lifestyle changes have been implicated in significantly
ncreased risks of lower urinary tract symptoms. Associated dietary
actors implicated include meat and high fat intake and it has been
uggested that these might be viable considerations in the prevention
nd treatment of LUTS [54].
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s earlier discussed, inflammation plays a major role in the aeti-
logy of both MetS and LUTS. Dietary fatty acids can modulate
arkers of inflammation and consumption of high fat diets has been
hown to increase concentrations of CRP [55]. Reports from the
arvard Women’s Health Study showed a progressive increase in
lood levels of hs-CRP with increasing glycemic index (GI). Dietary
lycemic Index (GI) is the mean propensity of carbohydrate in an
ndividual’s diet to increase blood glucose level [56]. Another study
arried out in the Netherlands also showed the same trend [66]. Lev-
ls of saturated fatty acids (SFAs) in the diet have been positively
orrelated with hs-CRP [57] and a study in Indian youths revealed
ietary saturated fatty acids (SFA) as the singularly most important
utrient responsible for increases in hs-CRP levels [58]. On the other
and, dietary polyunsaturated fatty acids (PUFA), and especially -
 PUFA, have been reported in several studies as having an inverse
ssociation with hs-CRP and other systemic markers of inflamma-
ion [59–61]. A review of experimental data reported that the acute
nflammatory response to a single meal is influenced by the quan-
ity and quality of dietary fat it contains. The authors concluded that
FA content is a major contributing factor to the magnitude of post-
randial inflammatory response [62]. Carotenoids [63], flavonoids
64], magnesium [65], and fruits/vegetable consumption [66] have
een reported to have an inverse association with hs-CRP.
s outlined above, insulin is another main factor implicated in both
etS and LUTS. Energy dense/high fat diets have a strong pos-
tive association with obesity and according to the World Health
rganisation, are major contributors to overweight and obesity [67].
besity in turn is responsible for insulin insensitivity which is the
ajor link among all MetS components and also causes prostatic
nlargement. A high fat/high sucrose diet has been reported to
educe insulin sensitivity [68]. Maegawa et al. also observed that
nimals in a high sucrose group had highly elevated insulin levels,
nd this was also elevated in a different high-fat group [69]. High
ietary fat intake is also a major influence on insulin action. Epi-
emiological and experimental evidence have linked high fat intake
ith insulin insensitivity/resistance [70] and the causative pathway
or fat-induction of insulin resistance has been linked to Leptin activ-
ty in the body [71]. Leptin also has effects on adipocyte secretion
71] which in turn influences testosterone secretion [15].
alcium has earlier been identified as having beneficial effects in
anagement of body weight [72] via possible mechanisms of pro-
oting lipolysis and inhibiting lipogenesis [73–75]. Reports suggest
hat in middle-aged males, introduction of calcium-channel blockers
ay be associated with increased severity of Lower Urinary Tract
ymptoms [76]. These calcium-channel blockers are commonly
sed to treat a wide range of cardiovascular disorders but increased
everity of LUTS was reported in the findings of Elhebir et al. Their
esults demonstrated that users of calcium antagonists had a higher
ikelihood of medical or surgical treatment for LUTS [77]. It can
herefore be assumed that increases in calcium intake via diet could
ave a beneficial effect in individuals with both metabolic syndrome
nd LUTS, pointing to a possible relationship in the mechanisms for
oth.
onclusionhe relationships between diet, metabolic syndrome and lower uri-
ary tract symptoms are diverse and there are sundry mechanisms
y which these associations occur. Serum CRP, insulin and testos-
erone, being common factors in both metabolic syndrome and lower
[T.G. Adedeji et al.
rinary tract symptoms, attest to an association between the two.
his lends even greater credence to a linkage between them; a
inkage which could be exploited in deriving new therapies and
nvestigations into these related conditions. Dietary interventions
ould be a mainline therapy for patients with metabolic syndrome
xhibiting lower urinary tract symptoms but the extent of associa-
ions will have to be further investigated. Further research is required
o clarify this relationship.
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